This document appears to be a press release announcement from Intensity Therapeutics, a biotechnology company. The main points of the announcement are:

1. New Clinical Trial Initiated: Intensity Therapeutics has initiated a new clinical trial, INVINCIBLE-4 (NCT06358573), which is part of a Phase 2/3 program evaluating INT2306, a novel engineered chemistry that enables aqueous cytotoxic-containing drug formulations to mix and saturate a tumor's dense, high-fat, pressurized environment. The trial focuses on patients with presurgical triple-negative breast cancer.
2. Primary Endpoint: Pathological Complete Response (pCR) is the primary endpoint for this clinical trial.
3. Development Objectives: The goal of INT2306 is to create a new approach to cancer cell death that shifts the treatment paradigm and turns many deadly cancers into chronic diseases, even for malignancies that do not respond to conventional immunotherapy.
4. Safety and Efficacy Profile: The INVINCIBLE-2 Study (NCT04781725) has demonstrated the ability of INT2306 to kill tumors and elicit an adaptive immune response within days of injection.

The document also includes a warning about forward-looking statements, cautioning investors and readers not to place undue reliance on these statements, which reflect management's current estimates, projections, expectations, and beliefs.